Elicio Berriz

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, November 9, 2023
Granzyme, Natural history, Antigen, Safety, Annual general meeting, DNA, Therapy, Risk, Peptide, Clinical trial, Mouse, Insurance, Patient, Research and development, Immunotherapy, PDAC, G&A, Lymph, Lymphatic system, RFS, Conference, BRAF, Cancer, Development, Pancreatic cancer, Death, SITC, V600E, Phase II, Neoplasm, AMP, OS, Society, AACR, Pharmaceutical industry, Vaccine, Amphiphile, Research, Elicio Berriz

R&D Expense: R&D expense for the third quarter of 2023 was $7.3 million, compared to $4.6 million for the third quarter of 2022.

Key Points: 
  • R&D Expense: R&D expense for the third quarter of 2023 was $7.3 million, compared to $4.6 million for the third quarter of 2022.
  • G&A Expense: G&A expense for the third quarter of 2023 was $3.5 million, compared to $1.2 million for the third quarter of 2022.
  • Net Loss and Net Loss per Share: Net loss for the third quarter of 2023 was $10.7 million, compared to $7.2 million for the third quarter of 2022.
  • Net loss per share for the third quarter of 2023 was $1.27 compared to $22.67 for the third quarter of 2022.

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

Retrieved on: 
Thursday, September 7, 2023
Vaccine, Antigen, University, Doctor of Philosophy, AMP, Neoplasm, CMC, Cancer, Lung cancer, BRAF, Research and development, Development, Patient, Lymph, Melanoma, Immune system, Therapy, IND, Pharmaceutical industry, Elicio Berriz, Research

This $2.6 million grant is an addition to the $2.8 million that it awarded Elicio in September 2022.

Key Points: 
  • This $2.6 million grant is an addition to the $2.8 million that it awarded Elicio in September 2022.
  • Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations.
  • Both vaccines have been designed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) platform that “educates” T cells on how to target particular antigens, such as mutated proteins in cancer.
  • We’re proud to support Elicio as they move their unique approaches into the clinic, and we look forward to this ongoing line of research.”

Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer

Retrieved on: 
Tuesday, September 5, 2023
KRAS, AACR, AMP, Neoplasm, Elicio Berriz, Pancreatic cancer, Cancer, Oncology, MRD, Lustgarten Foundation for Pancreatic Cancer Research, Patient, Pancreas, MSK, Memorial Sloan Kettering Cancer Center, Therapy, Conference, Safety, Pharmaceutical industry

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that additional data from the Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, will be presented in a poster presentation at the upcoming AACR Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts from September 27-30, 2023.

Key Points: 
  • BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that additional data from the Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, will be presented in a poster presentation at the upcoming AACR Special Conference on Pancreatic Cancer taking place in Boston, Massachusetts from September 27-30, 2023.
  • These data are in addition to the interim data Elicio presented at the ASCO Annual Meeting earlier this year.
  • ELI-002 2P is a therapeutic cancer vaccine candidate that was designed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to treat cancers driven by G12D and G12R mutations in KRAS.
  • AMPLIFY-201 is a multicenter Phase 1 trial assessing the safety, immunogenicity and antitumor activity of ELI-002 in patients with mutant KRAS-driven tumors who are at high risk for relapse due to detection of minimal residual disease (MRD) following standard surgery and chemotherapy.

Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

Retrieved on: 
Monday, August 28, 2023
Central Florida, KRAS, University, General counsel, Employment, Drug development, Senior, Blank Rome, Public policy, Mirati Therapeutics, Statistics, Clinical trial, Elicio Berriz, Cancer, TAP, Research, NSCLC, Boston University, History, Strategic planning, Patient, Rutgers School of Dental Medicine, Corporation, Corporate lawyer, Rutgers Journal of Law & Public Policy, FDA, Therapy, Rutgers Law School, Pharmaceutical industry, Wat Bang Khun Thian Nok, Biogen, Biometrics, Mirati, Law

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics.

Key Points: 
  • BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics.
  • She joined Molecular Templates as Corporate Counsel and during her time there, held roles of increasing responsibility, becoming General Counsel in February 2022.
  • Thian Kheoh, Ph.D., has over 30 years of drug development and clinical trial experience in the biopharmaceutical industry.
  • He most recently served as Vice President of Biometrics at Mirati Therapeutics where he led the Biometrics team in obtaining the FDA approval of KRAZATI® for KRAS G12C NSCLC patients.

Elicio Therapeutics Reports Inducement Grants

Retrieved on: 
Tuesday, August 22, 2023
Cancer, Employment, Therapy, Pharmaceutical industry, Elicio Berriz

BOSTON, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on August 21, 2023, the Company’s board of directors approved the grant of 72,980 inducement stock options to two new employees, as an inducement material to each employee entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • BOSTON, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on August 21, 2023, the Company’s board of directors approved the grant of 72,980 inducement stock options to two new employees, as an inducement material to each employee entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each grant provides for the purchase of shares of Elicio common stock at a price of $9.99 per share, the closing price per share of Elicio common stock as reported by Nasdaq on August 21, 2023, the date of grant.
  • The grants vest over four years, with 25 percent of the shares vesting on the first anniversary of each employee’s respective start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such employee’s continued service relationship with Elicio through the applicable vesting dates.

Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update

Retrieved on: 
Tuesday, June 6, 2023
KRAS, Antigen, AMP, Neoplasm, Cancer, BRAF, Mutation, Toxicity, History, Biomarker, Immunotherapy, ASCO, MRD, Development, Cytokine release syndrome, Patient, Lymph, Therapy, Fine chemical, Pharmaceutical industry, Elicio Berriz, Research

Elicio’s primary focus will continue to be the advancement of lead candidate, ELI-002, an investigational immunotherapy, through clinical trials.

Key Points: 
  • Elicio’s primary focus will continue to be the advancement of lead candidate, ELI-002, an investigational immunotherapy, through clinical trials.
  • “I’m proud to lead Elicio at this exciting time when we’ve executed a successful merger and have presented positive data on ELI-002 at this year’s ASCO Meeting,” said Robert Connelly, Chief Executive Officer at Elicio Therapeutics.
  • “Over the last two years, our team has worked tirelessly to meet our financial and pipeline milestones.
  • I’m pleased to welcome Brian and his public company experience to the leadership team as we transition to a Nasdaq-listed company.

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

Retrieved on: 
Saturday, June 3, 2023
KRAS, Therapy, AMP, McCormick Place, Neoplasm, Aes, Elicio Berriz, Pancreatic cancer, Cancer, Toxicity, Oncology, Biomarker, ASCO, MRD, Research and development, Development, Phase 1, Literature, American Society of Clinical Oncology, Lustgarten Foundation for Pancreatic Cancer Research, Patient, Cytokine release syndrome, Lymph, Physician, Colorectal cancer, Risk, Immune system, Annual general meeting, MSK, Memorial Sloan Kettering Cancer Center, Toxic epidermal necrolysis, Safety, Society, Pancreatic tumor, Caregiver, Peptide, Pharmaceutical industry, Vaccine, Phosphorus, Research

This study evaluated ELI-002 2P, a 2-peptide formulation designed to treat cancers driven by G12D and G12R mutations in KRAS.

Key Points: 
  • This study evaluated ELI-002 2P, a 2-peptide formulation designed to treat cancers driven by G12D and G12R mutations in KRAS.
  • Responses were observed at all dose levels, with a high proportion of patients having tumor biomarker reduction including a subset with clearance.
  • Mutant KRAS drives 25% of solid human cancers with an overall poor prognosis and high relapse risk and limited therapeutic options.
  • Elicio has developed a broad spectrum 7-peptide formulation of ELI-002 currently being assessed in a Phase 1/2 study ( NCT05726864 ).

Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer

Retrieved on: 
Friday, June 2, 2023
Cancer, Employment, Therapy, Pharmaceutical industry, Elicio Berriz

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the grant of an inducement award to the Company’s newly appointed Chief Financial Officer, Brian Piekos.

Key Points: 
  • BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the grant of an inducement award to the Company’s newly appointed Chief Financial Officer, Brian Piekos.
  • In connection with Mr. Piekos’ appointment, the Elicio Board of Directors approved a stock option grant to Mr. Piekos as an inducement material to Mr. Piekos entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock option provides for the purchase of up to 75,484 shares of Elicio common stock at a price of $10.00 per share, the closing price per share of Elicio common stock as reported by Nasdaq on June 1, 2023, the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Mr. Piekos’ employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Mr. Piekos’ continued service relationship with Elicio through the applicable vesting dates.

Elicio Therapeutics Announces Completion of Merger with Angion Biomedica

Retrieved on: 
Thursday, June 1, 2023
P.C, KRAS, AMP, Cancer, MBA, ASCO, Cooley LLP, MD, Inc., Patient, Oppenheimer Holdings, Therapy, Pharmaceutical industry, Elicio Berriz

Shares of Elicio to commence trading on Nasdaq under the ticker symbol “ELTX” on June 2, 2023

Key Points: 
  • Shares of Elicio to commence trading on Nasdaq under the ticker symbol “ELTX” on June 2, 2023
    BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the closing of its previously announced merger with Angion Biomedica Corp.
  • “Joining the Nasdaq stock exchange through the reverse merger with Angion marks a significant milestone in Elicio’s growth.
  • We remain on track as we advance our proprietary lymph node-targeting Amphiphile (AMP) technology to develop cancer immunotherapies,” said Robert Connelly, Chief Executive Officer of Elicio.
  • The management team of Elicio has become the management team of the combined company, led by Robert Connelly as Chief Executive Officer.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FRBA, MLVF, MPB, ANGN

Retrieved on: 
Thursday, April 13, 2023
Fraud, Therapy, First Bank, Advertising, Sale, Security (finance), Elicio Berriz

If you are a First Bank shareholder, click here to learn more about your legal rights and options .

Key Points: 
  • If you are a First Bank shareholder, click here to learn more about your legal rights and options .
  • If you are a Malvern shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.